China plans to build Africa’s first local insulin production facility in Nigeria, a project expected to transform blood glucose level management, prevent diabetes-related complications, and end the country’s reliance on imported insulin. According to Chinese Ambassador to Nigeria, Yu Dunhai, this facility will position Nigeria as a hub for African medical biotechnology, providing a significant boost to the country’s healthcare sector.
Project Details:
– Partnership: The project is part of China’s commitment to expanding its comprehensive strategic partnership with Nigeria, with Shanghai Haiqi Industrial Company Limited signing a Memorandum of Agreement (MoA) with the National Biotechnology Research and Development Agency (NBRDA).
– Objective: Local production of insulin will enhance medical self-sufficiency, spur industrial innovation, reduce import bills, and provide hope to families struggling with the rising cost of diabetes treatment.
– Impact: With over 3 million Nigerians living with diabetes, this project is expected to have a significant impact on the country’s healthcare sector.
Benefits:
– Increased Access to Insulin: The facility will improve access to affordable insulin for millions of Nigerians living with diabetes.
– Economic Benefits: The project is expected to reduce Nigeria’s reliance on imported insulin, saving billions of naira in foreign exchange.
– Strengthened Bilateral Relations: The project demonstrates the growing value of Chinese investment in Nigeria’s economy and healthcare sector.
